Last reviewed · How we verify
Arificial Tear
Artificial tears are lubricating eye drops that supplement or replace the eye's natural tear film to relieve dryness and irritation.
Artificial tears are lubricating eye drops that supplement or replace the eye's natural tear film to relieve dryness and irritation. Used for Dry eye syndrome, Ocular surface irritation and discomfort.
At a glance
| Generic name | Arificial Tear |
|---|---|
| Also known as | Placebo, Artificial Tear |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Drug class | Ophthalmic lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Artificial tears mimic the composition and function of natural tears, providing lubrication to the ocular surface and protecting the cornea and conjunctiva from desiccation. They help restore the tear film's protective barrier, reduce friction during blinking, and provide comfort by moisturizing dry eye tissues. These formulations typically contain water, electrolytes, and viscosity agents to maintain prolonged contact with the eye surface.
Approved indications
- Dry eye syndrome
- Ocular surface irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation
- Allergic reaction (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arificial Tear CI brief — competitive landscape report
- Arificial Tear updates RSS · CI watch RSS
- Massachusetts Eye and Ear Infirmary portfolio CI